Liraglutide: Side Effects

Safety Overview#

Liraglutide has been evaluated in extensive clinical programs including LEAD (T2D, >4,000 participants), LEADER (cardiovascular outcomes, 9,340 participants), and SCALE (obesity, >5,000 participants). The safety profile is well characterized through these programs and over 15 years of post-marketing surveillance since Victoza approval in January 2010.

Gastrointestinal Adverse Events#

The most frequently reported adverse events with liraglutide are gastrointestinal, consistent with the GLP-1 receptor agonist mechanism of action.

Nausea is the most common adverse event. In the SCALE Obesity trial (Saxenda 3.0 mg), nausea was reported in 39.3% of liraglutide patients versus 13.8% placebo. In LEAD trials (Victoza 1.8 mg), rates were lower at 12-15%. Nausea is dose-related, predominantly mild to moderate, most common during dose escalation, and tends to diminish with continued treatment. In the SCALE program, fewer than 4% of patients discontinued due to nausea.

Vomiting occurs in 15.7% of Saxenda patients versus 3.9% placebo. Like nausea, it is most common during dose escalation and usually transient.

Diarrhea is reported in 20.9% of Saxenda patients versus 9.9% placebo, usually mild and self-limiting.

Constipation occurs in 19.4% of Saxenda patients versus 8.5% placebo, attributed to slowed GI transit.

Higher incidences with Saxenda reflect the higher maintenance dose (3.0 mg vs 1.8 mg).

Dose Escalation and GI Tolerability#

The dose escalation schedules for both Victoza and Saxenda were specifically designed to minimize GI adverse events. Key principles:

• Most GI adverse events occur in the first days after each dose increase
• Symptoms typically diminish within 1-2 weeks at each dose level
• Patients who cannot tolerate a dose increase may extend the time at the current dose
• The 4-week Saxenda escalation (0.6 to 3.0 mg) significantly reduces nausea incidence compared to immediate full-dose initiation

Heart Rate Effects#

Liraglutide is associated with a modest increase in resting heart rate, typically 2-3 beats per minute. This is a GLP-1 agonist class effect and is generally not clinically significant. In the LEADER trial, no increased risk of heart failure was observed despite the heart rate increase.

Injection Site Reactions#

Injection site reactions (erythema, pruritus, rash) are reported in approximately 2% of patients and are generally mild. Rotating injection sites and allowing the pen to reach room temperature can minimize these reactions.

Hepatobiliary Effects#

Cholelithiasis and cholecystitis are reported more frequently with liraglutide than placebo, particularly in weight management trials. In the SCALE program, cholelithiasis was reported in 2.5% of liraglutide patients versus 0.8% placebo. Rapid weight loss increases gallstone risk.

Lipase and amylase elevations are commonly observed without clinical pancreatitis. Isolated enzyme elevations are not considered actionable in the absence of symptoms.

Thyroid Effects (Boxed Warning)#

Liraglutide carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data. This is a class-wide warning for all GLP-1 receptor agonists. Epidemiologic data over 15+ years of GLP-1 agonist use have not confirmed this risk in humans. Patients should report neck lumps, difficulty swallowing, or persistent hoarseness.

Pancreatitis#

Acute pancreatitis has been reported with liraglutide in clinical trials and post-marketing. In the LEADER trial, the incidence was low (0.4% liraglutide vs 0.5% placebo, not statistically significant). Patients should report persistent severe abdominal pain, and liraglutide should be discontinued if pancreatitis is suspected.

Contraindications#

• MTC or MEN2 history: Absolute contraindication (boxed warning)
• Pregnancy: May cause fetal harm; discontinue immediately if pregnancy detected
• Known hypersensitivity: Prior serious allergic reaction to liraglutide or excipients
• Other GLP-1 agonists: Do not use concomitantly with semaglutide, exenatide, or other GLP-1 RAs

Drug Interactions#

Insulin and sulfonylureas: Most important interaction. Increased hypoglycemia risk requires dose reduction of concomitant agents when initiating liraglutide.

Oral contraceptives: Gastric emptying delay may reduce absorption. Consider non-oral contraception as backup during initiation and dose escalation.

Oral medications generally: Delayed gastric emptying may affect absorption kinetics of co-administered oral drugs. Particularly relevant for drugs with narrow therapeutic indices (warfarin, digoxin, levothyroxine).

CYP interactions: Liraglutide is not metabolized by CYP enzymes. CYP-mediated pharmacokinetic interactions are not expected.

Special Populations#

• Renal impairment: No dose adjustment required. Monitor for dehydration-related AKI during GI events.
• Hepatic impairment: No dose adjustment required. Use with caution.
• Elderly (65 and over): No dose adjustment required. Comparable safety in clinical trials.
• Pediatric: Saxenda approved for adolescents 12-17 years. GI adverse events were more common (65%) than in adult populations.

Related Reading#

• Liraglutide overview and research guide
• Liraglutide dosing protocols
• Liraglutide risks and legal status